Related Experiment Video
Updated: Jan 29, 2026

Production and Detection of Reactive Oxygen Species ROS in Cancers
Published on: November 21, 2011
Adverse Outcome Pathway 298: Increase in Reactive Oxygen Species Leading to Human Treatment-Resistant Gastric Cancer
Shihori Tanabe1, Sabina Quader2, Ryuichi Ono3
1Division of Risk Assessment, Center for Biological Safety and Research, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki-ku, Kawasaki 210-9501, Japan.
Abstract:
Injury causes resistance in human gastric cancer. Adverse Outcome Pathway (AOP) 298, entitled "increase in reactive oxygen species (ROS) leading to human treatment-resistant gastric cancer," consists of "increase in ROS" as a molecular initiating event (MIE), followed by a series of key events (KEs), namely "porcupine-induced Wnt secretion and Wnt signaling activation," "beta-catenin activation," and "epithelial-mesenchymal transition (EMT)," and the adverse outcome (AO) of "treatment-resistant gastric cancer" in the sequence. AOP 298 includes four KE relationships (KERs): "increase in ROS leads to porcupine-induced Wnt secretion and Wnt signaling activation," "porcupine-induced Wnt secretion and Wnt signaling activation leads to beta-catenin activation," "beta-catenin activation leads to EMT," and "EMT leads to treatment-resistant gastric cancer." ROS has multiple roles in disease, such as in the development and progression of cancer, or apoptotic induction, causing anti-tumor effects. Regarding AOP 298, we focus on the role of sustained chronic ROS levels in inducing therapy resistance in human gastric cancer. EMT, induced by Wnt/beta-catenin signaling, demonstrates cancer stem cell-like characteristics in human gastric cancer.
Insights
Increased reactive oxygen species (ROS) drive treatment resistance in human gastric cancer by activating Wnt/beta-catenin signaling and epithelial-mesenchymal transition (EMT). This pathway highlights a key mechanism for gastric cancer therapy resistance.
Area of Science:
- Oncology
- Molecular Biology
- Toxicology
Background:
- Gastric cancer exhibits resistance to treatments.
- Adverse Outcome Pathway (AOP) 298 links increased reactive oxygen species (ROS) to treatment-resistant gastric cancer.
- ROS plays multifaceted roles in cancer, including progression and apoptosis induction.
Purpose of the Study:
- To elucidate the role of sustained chronic ROS levels in inducing therapy resistance in human gastric cancer.
- To detail the sequence of events in AOP 298, from ROS increase to treatment resistance.
Main Methods:
- The study outlines Adverse Outcome Pathway (AOP) 298, detailing key events and relationships.
- Focuses on the molecular initiating event (MIE) of increased ROS and subsequent key events (KEs).
- Examines the pathway involving porcupine-induced Wnt secretion, beta-catenin activation, and epithelial-mesenchymal transition (EMT).
Main Results:
- AOP 298 describes a causal chain: increased ROS → Wnt signaling activation → beta-catenin activation → EMT → treatment-resistant gastric cancer.
- Sustained chronic ROS levels are identified as a driver of therapy resistance in gastric cancer.
- EMT, mediated by Wnt/beta-catenin signaling, confers cancer stem cell-like characteristics.
Conclusions:
- The Wnt/beta-catenin signaling pathway and subsequent EMT are critical mediators of ROS-induced gastric cancer treatment resistance.
- Understanding AOP 298 provides insights into mechanisms of therapeutic failure in gastric cancer.
- Targeting ROS or downstream pathways like Wnt/beta-catenin/EMT may offer strategies to overcome treatment resistance.
Related Concept Videos
Treatment Resistant Cancers
Formation of Species
What is a Species?
Keystone Species
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...

